The authors explicitly state that further trials are warranted to confirm these outcomes, as retrospective observational data cannot establish causality. Prospective RCTs are essential to validate these promising neuroprotective signals and guide clinical practice. Gap type: open_question Source paper: Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. (2025, JAMA network open, PMID:40663350)
Landscape Summary: Can randomized controlled trials confirm the neuroprotective effects observed in this retrospective cohort? is a 0.82 priority gap in clinical neuroscience. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
Can randomized controlled trials confirm the neuroprotective effects observed in this retrospective cohort? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: